PRIMARY STUDY
Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson’s Disease. Induced by MPTP.
Key Findings: These results indicate that BCP acts via multiple neuroprotective mechanisms in our murine model and suggest that BCP may be viewed as a potential treatment and/or preventative agent for PD.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Mexico, Spain, Switzerland
Year of Pub: 2017
Cannabinoids Studied: AM-x Synthetic Cannabinoids
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB2
Ligands Studied: Anti-inflammatory cytokines, Dopamine, Pro-inflammatory cytokines
Dosage: BCP (10 mg/kg, i.p. and 10 mg/kg through an oral gavage) for 5 consecutive days. The protective effect of BCP against astrocyte activation and microglia was fully reversed by pre-treating with 3 mg/kg AM630.
Route of Administration: Injection, Oral (Ingestion)
Link to study
